Breast Cancer

Erika Hamilton, MD

Hamilton

Breast Cancer

Erika Hamilton, MD

SCRI, will deliver two oral presentations, including “Vepdegestrant, a PROTAC Estrogen Receptor Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 –Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study” in the Oral Abstract Session, Breast Cancer—Metastatic on Saturday, May 31 at 1:15 p.m. CDT in Hall B1 and “Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin , a Novel B7-H4-Directed Dolasynthen Antibody-Drug Conjugate” during the Rapid Oral Abstract Session, Development Therapeutics—Molecularly Targeted Agents and Tumor Biology on Monday, June 2 at 8 a.m. CDT in S406.